Navigating TRIPS Provisions: Balancing IP Rights and Competition Law

When a company holds a patent, it has the legal right to exclude everyone else from using that invention – that is precisely the point of intellectual property protection. But what happens when this exclusivity is used not to reward innovation, but to lock out competition, inflate prices, or block the flow of technology to countries that desperately need it? The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS), which came into force on 1 January 1995, grappled directly with this tension. It is the most comprehensive multilateral agreement on intellectual property to date – and built into its very structure is an acknowledgment that IP rights can be abused, and that competition policy must step in when they are.

What TRIPS actually does 🔗

TRIPS was negotiated at the end of the Uruguay Round of GATT and is administered by the World Trade Organization (WTO). It establishes minimum standards for the protection of seven categories of intellectual property: copyrights, trademarks, geographical indications, industrial designs, patents, layout designs of integrated circuits, and undisclosed information (trade secrets). Its three central pillars are standards of protection, enforcement mechanisms, and a dispute settlement framework that subjects IP-related disagreements between WTO members to WTO procedures.

Crucially, TRIPS sets a floor, not a ceiling. Members are free to provide stronger protection than the minimum – and many bilateral “TRIPS-plus” agreements push countries to do exactly that – but they cannot fall below the baseline. This design choice has enormous implications for developing countries, who must comply with the same minimum obligations as wealthy, IP-exporting nations.

The objectives and principles: Articles 7 and 8 🔗

Two provisions are foundational to understanding how TRIPS tries to balance IP protection with the broader public interest: Articles 7 and 8.

Article 7 sets out the objectives of the Agreement. It states that the protection and enforcement of IP rights should contribute to the promotion of technological innovation, as well as the transfer and dissemination of technology, for the mutual benefit of producers and users of knowledge, and in a manner that supports social and economic welfare. This is a significant statement. It frames the IP system not as an end in itself, but as a social policy tool – one that must deliver real-world benefits beyond the interests of rights holders alone. Article 7 explicitly treats technology transfer as an objective, not merely a side effect, of IP protection.

Article 8 goes further. It recognises the right of members to adopt measures necessary to protect public health and nutrition, and to promote public interest in sectors of vital importance to their socio-economic and technological development. Paragraph 2 of Article 8 is particularly important: it acknowledges that appropriate measures may be needed to prevent the abuse of IP rights by right holders or resort to practices that unreasonably restrain trade or adversely affect the international transfer of technology. The Indian government has formally argued in the WTO that Articles 7 and 8 should be treated as overarching provisions that qualify and contextualise every other provision in TRIPS that protects IP rights.

Where competition law enters: Article 40 🔗

If Articles 7 and 8 set the philosophy, Article 40 provides the operational mechanism through which competition policy intersects with IP law under TRIPS.

Article 40 recognises that certain licensing practices or conditions pertaining to IP rights that restrain competition may have adverse effects on trade and may impede the transfer and dissemination of technology. This is a frank acknowledgment from within the Agreement itself that IP monopolies are not automatically benign. Article 40.1 makes the problem explicit: the restraint of competition through IP licensing is a real concern that the Agreement cannot ignore.

Article 40.2 then gives WTO members the authority to act. It permits members to specify in their domestic law licensing practices or conditions that may constitute an abuse of IP rights having an adverse effect on competition in the relevant market, and to adopt appropriate measures to prevent such effects. The provision provides illustrative examples – exclusive grant-backs and coercive package licensing – but the list is not exhaustive. Members retain significant discretion to define what counts as anti-competitive conduct in the IP licensing context.

Article 40.3 and 40.4 add a consultative mechanism. If one member believes another is violating its domestic competition rules through the licensing conduct of an IP holder who is a national of the first country, the affected member can request consultations. This stops short of a binding enforcement mechanism – TRIPS does not impose a uniform competition law on all members – but it creates a framework for dialogue and cooperation.

Compulsory licensing and the check on IP monopolies 🔗

One of the most powerful tools TRIPS allows against IP abuse is compulsory licensing, governed by Article 31. A compulsory licence allows a government to authorise the use of a patented invention without the consent of the patent holder, subject to conditions including adequate remuneration. TRIPS permits compulsory licensing in a range of circumstances, including national emergencies and public non-commercial use. Importantly, Article 31(k) explicitly allows compulsory licensing as a remedy for anti-competitive practices, and in such cases many of the usual conditions – like the requirement to first seek a voluntary licence – may be waived.

India has used this provision. The most prominent example came in 2012 when the Indian Patent Office granted the country’s first compulsory licence to Natco Pharma for Bayer’s cancer drug Nexavar, citing the drug’s unaffordability and Bayer’s failure to work the patent in India. The Patents Act, 1970, under Section 84, allows compulsory licensing after three years of a patent grant if working requirements are not met – a provision that the Indian legislature designed in alignment with TRIPS flexibilities.

Flexibilities for developing countries 🔗

The TRIPS Agreement is often criticised for imposing a one-size-fits-all framework on countries at very different stages of development. However, embedded within it are several flexibilities that developing and least-developed countries can use to pursue their own policy objectives.

Transitional periods were built in from the start. Developing countries were given a longer period to phase in their obligations, and special transition arrangements applied to pharmaceutical product patents. For least-developed countries, these periods have been extended multiple times. The 2001 Doha Declaration on TRIPS and Public Health reaffirmed that the Agreement should be interpreted and implemented in a manner supportive of WTO members’ right to protect public health, directly responding to developing-country concerns that TRIPS was being read too narrowly by developed nations.

WIPO identifies several categories of TRIPS flexibilities that countries can exploit: the freedom to determine how TRIPS concepts are implemented within their own legal systems (Article 1.1); exceptions to rights conferred, such as experimental use and the “Bolar” exception that allows generic drug manufacturers to begin regulatory approval processes before a patent expires; and limitations on enforcement measures so they do not distort market competition. Critically, TRIPS does not require undisclosed information (trade secrets) to be treated as a form of property – it requires protection against unfair commercial use, but leaves considerable room for domestic legislative design.

The India-TRIPS relationship: a study in strategic engagement 🔗

India’s engagement with TRIPS has never been passive. India was among the countries that actively opposed the inclusion of IP standards in GATT negotiations, arguing that rigid IP protection impeded developing countries’ access to technology and distorted trade. That opposition was eventually overcome, but India has since worked within the TRIPS framework to use every available flexibility.

Under domestic law, the interplay between IP and competition is managed through the Competition Act, 2002. Section 3(5) creates a blanket exception for the exercise of IP rights, meaning that IP holders can legitimately restrict the use of their rights without automatically violating competition law. However, Section 4 of the Act addresses abuse of dominant position, which can catch IP holders who impose unfair prices or conditions, limit supply, or deny market access. The Competition Commission of India (CCI) has become increasingly active in policing the boundary between legitimate IP exercise and anti-competitive conduct, particularly in the technology sector.

India has also formally communicated to the WTO TRIPS Council that Articles 7 and 8.2 should be treated as overarching provisions qualifying the entire Agreement, and that Articles 40, 66.2, and 67 (which relate to technology transfer to least-developed countries and technical cooperation) must be effectively implemented to fulfil TRIPS’ development objectives. This position reflects a deliberate interpretive strategy: using the Agreement’s own language to push back against the narrowing of flexibilities.

The anti-competitive licensing problem in practice 🔗

To understand why Article 40 matters, consider what unchecked IP licensing can look like. A patent holder in a pharmaceutical, technology, or software market can structure licences to require recipients to assign back any improvements they develop (exclusive grant-backs), effectively concentrating future innovation within the licensor. They can bundle unrelated IP into mandatory package licences, forcing licensees to pay for rights they do not need. They can set royalty rates that make downstream products unaffordable, or grant exclusive territorial licences that partition markets and eliminate price competition between licensees in different countries.

Each of these practices sits at the intersection of IP law and competition law. IP law creates the right; competition law regulates its exercise. TRIPS, through Article 40, acknowledges that these regulatory domains must coexist – and gives member states the legal authority to ensure that they do. The absence of a binding, uniform international competition law within TRIPS means this remains primarily a task for domestic legislators, but the Agreement’s explicit recognition of the problem legitimises national action and provides a defence against challenges through WTO dispute settlement.

TRIPS-plus pressures and the erosion of flexibilities 🔗

A persistent concern for developing countries is the pressure to go beyond TRIPS standards through bilateral and regional free trade agreements. A UN High-Level Panel on Innovation and Access to Health Technologies specifically recommended that countries refrain from demanding trading partners implement IP obligations beyond TRIPS – yet TRIPS-plus provisions continue to appear in FTAs negotiated by major economies. These provisions often restrict the application of compulsory licences, extend patent terms, and add data exclusivity rules that delay generic competition.

For India, these pressures are particularly acute given the Indian pharmaceutical industry’s role as a global supplier of affordable medicines. Flexibilities in enforcement – such as the cautious grant of provisional injunctions and the possibility of denying permanent injunctions for public health reasons – are of crucial importance for maintaining a pro-competitive IP system. The erosion of these flexibilities through TRIPS-plus commitments would have consequences well beyond India’s borders.

What do you think? If TRIPS already contains provisions like Article 40 to control anti-competitive IP licensing, why do developing countries continue to struggle to use these flexibilities effectively in practice – and should international law go further by establishing binding minimum standards for competition policy in IP-related markets? India has formally argued that Articles 7 and 8 should override other TRIPS provisions when they conflict: do you think this interpretive position is legally sound, or does it risk undermining the certainty that IP holders rely on to invest in innovation?

References

1. https://www.wto.org/english/tratop_e/trips_e/intel2_e.htm
2. https://www.uspto.gov/ip-policy/patent-policy/trade-related-aspects-ip-rights
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC9790950/
4. https://commerce.gov.in/international-trade/india-and-world-trade-organization-wto/indian-submissions-in-wto/trade-related-aspects-of-intellectual-property-rightstrips/council-for-trade-related-aspects-of-intellectual-property-rights-communication-from-india-2/
5. https://www.mondaq.com/india/trademark/1117244/analyzing-the-intersection-of-competition-law-and-ipr
6. https://www.zestip.in/the-interface-between-ipr-and-competition-law/
7. https://en.wikipedia.org/wiki/TRIPS_Agreement
8. https://www.wipo.int/ip-development/en/policy_legislative_assistance/advice_trips.html
9. https://legalservicesindia.com/law/article/1031/7/A-To-Z-of-Trips-An-Agreement-on-Trade-Related-Aspects-of-Intellectual-Property-Rights
10. https://link.springer.com/chapter/10.1007/978-3-030-83114-1_1